These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 14557495)

  • 1. Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.
    Mitsiades CS; Sykoutri D; McMullan C; Poulaki V; Mitsiades N
    J Clin Endocrinol Metab; 2003 Oct; 88(10):5043-4; author reply 5044. PubMed ID: 14557495
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
    Dziba JM; Ain KB
    J Clin Endocrinol Metab; 2004 May; 89(5):2127-35. PubMed ID: 15126530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer.
    Rao AS; Kremenevskaja N; von Wasielewski R; Jakubcakova V; Kant S; Resch J; Brabant G
    J Clin Endocrinol Metab; 2006 Jan; 91(1):159-68. PubMed ID: 16263821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.
    Kim E; Matsuse M; Saenko V; Suzuki K; Ohtsuru A; Mitsutake N; Yamashita S
    Thyroid; 2012 Jul; 22(7):717-24. PubMed ID: 22650230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate in cutaneous melanoma.
    Redondo P; Lloret P; Andreu EJ; Inoges S
    J Invest Dermatol; 2004 Dec; 123(6):1208-9. PubMed ID: 15610538
    [No Abstract]   [Full Text] [Related]  

  • 6. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and phototoxicity of Hypocrellin A on malignant human cell lines, evidence of a synergistic action of photodynamic therapy with Imatinib mesylate.
    Chio-Srichan S; Oudrhiri N; Bennaceur-Griscelli A; Turhan AG; Dumas P; Refregiers M
    J Photochem Photobiol B; 2010 May; 99(2):100-4. PubMed ID: 20347325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    Uziel O; Fenig E; Nordenberg J; Beery E; Reshef H; Sandbank J; Birenbaum M; Bakhanashvili M; Yerushalmi R; Luria D; Lahav M
    Br J Cancer; 2005 May; 92(10):1881-91. PubMed ID: 15870711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
    Altuna X; Lopez JP; Yu MA; Arandazi MJ; Harris JP; Wang-Rodriguez J; An Y; Dobrow R; Doherty JK; Ongkeko WM
    Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
    Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
    Kurebayashi J; Okubo S; Yamamoto Y; Ikeda M; Tanaka K; Otsuki T; Sonoo H
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):460-70. PubMed ID: 16435154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate in polycythemia vera.
    Spivak JL; Silver RT
    Blood; 2004 Apr; 103(8):3241; author reply 3241-2. PubMed ID: 15070710
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
    van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
    Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly targeted therapy: have the floodgates opened?
    Druker BJ
    Oncologist; 2004; 9(4):357-60. PubMed ID: 15266089
    [No Abstract]   [Full Text] [Related]  

  • 19. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
    Lupino E; Ramondetti C; Buccinnà B; Piccinini M
    Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
    Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.